FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
GEPL Capital Ltd, ICICI Direct, KR Choksey Securities Ltd, S P Tulsian and InvestorGain.com have given "Apply" recommendation to Gland Pharma IPO. Capital Market, Dilip Davda and Kotak Securities have given "May Apply" recommendation to Gland Pharma IPO. Axis Capital has "Not Rated" the IPO.
Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 5 | 3 | 0 | 0 | 1 |
% | 55.56 | 33.33 | 0.00 | 0.00 | 11.11 |
Reviewer | Recommendation | Past Reviews |
---|---|---|
Axis Capital | Not Rated | |
Capital Market | May Apply | |
Dilip Davda | May Apply | |
GEPL Capital Ltd | Apply | |
ICICI Direct | Apply | |
Kotak Securities | May Apply | |
KR Choksey Securities Ltd | Apply | |
S P Tulsian | Apply | |
InvestorGain.com | Apply |
The Captial Market (CapitalMarket.com) rating for Gland Pharma IPO is 45. Their analysis recommends May subscribe for the IPO.
Reviewer | Rating Score | Rating |
---|---|---|
Capital Market | 45 | May subscribe |
[Dilip Davda] No doubt that currently, the pharma sector is attracting investors following COVID-19 pandemic and the search of remedies for it globally. This company has posted good performance for the last three fiscals and spectacular numbers for Q1 of FY21, but will it sustain going forward is a major concern in the present context of negative sentiment for China connections globally. Based on P/BV and P/E parameters, the issue appears fully priced. Considering all these, though it sounds lucrative bet for the long term, risk savvy, cash surplus investors may consider investment at their own risk in this China connected IPO. Read detail review...
Post Recommendation Manage Recommendations
Note:
Rs 0 Account Opening Fee
Free Eq Delivery & MF
Flat ₹20 Per Trade in F&O
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|